The consequences of greater net price transparency for innovative medicines in Europe

December 15, 2020
Pharma production

In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.

Related capabilities

Additional contributors